From
Medical News Today:
Two cases of acute liver failure in which the patients taking heart medication
dronedarone (Multaq) needed liver transplants have resulted in an FDA communication informing that data on the potential risk of liver injury are being added to the drug's labels.
Dronedarone (Multaq) is used to treat atrial fibrillation and atrial flutter in individuals whose hearts either returned to normal rhythm or who underwent drug therapy for electric shock treatment - the drug helps maintain normal rhythm. The FDA (Food and Drug Administration) approved dronedarone in July 2009, and it is available as 400mg tablets in 60 count bottles. The FDA did not approve the medication for reducing deaths. A study of patients with irregular heartbeats found that Multaq treatment more than doubles the risk of death.
Since its launch, approximately 200,000 people have taken Multaq.